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CASE REPORT
Imported Plasmodium vivax malaria 
with severe thrombocytopaenia: can it be 
severe malaria or not?
Spinello Antinori1*, Alberto Corona2, Anna Lisa Ridolfo1, Laura Galimberti1, Davide Ricaboni1, Laura Milazzo1 
and Mario Corbellino1
Abstract 
Background: Thrombocytopaenia is the most frequent malaria-associated haematologic alteration observed with all 
five Plasmodium parasites causing disease in humans. Although not included in the World Health Organization criteria 
for severe Plasmodium falciparum malaria, severe thrombocytopaenia has been increasingly mentioned as an indica-
tor of P. vivax malaria severity.
Case: Here, it is described a case of imported P. vivax malaria in a 37-year old man from Pakistan who presented with 
severe thrombocytopaenia (5 × 109/L). He was admitted to the intensive care unit and initially treated with a 1-day 
course of intravenous quinine followed by oral chloroquine and primaquine. The patient’s platelet count increased as 
early as 4 hours after treatment inception and the clinical course was favourable and uneventful.
Discussion: This case report, along with a review of published cases focusing on the relationship between thrombo-
cytopaenia and severe P. vivax malaria, suggests that the prognostic role of severe thrombocytopaenia is ambiguous 
in absence of severe haemorraghic complications and its use as diagnostic criterion of malaria severity may lead to 
overestimation of severe P. vivax malaria cases.
Conclusion: Due to the lack of high quality studies it is at present unclear if severe thrombocytopaenia in the setting 
of P. vivax malaria should be considered indicative of severe malaria.
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Background
Plasmodium vivax is responsible for nearly half of all 
malaria cases diagnosed outside sub-Saharan Africa and 
it exhibits the widest geographical distribution of human 
malaria parasites with an estimated 2.49 billion individu-
als living in areas at risk of infection [1]. Plasmodium 
vivax malaria has been long known as “benign tertian 
malaria” as opposed to the “malignant tertian or sub-
tertian malaria” caused by P. falciparum [2]. However, in 
recent years an increasing number of studies, especially 
from the Indian subcontinent and South America, have 
highlighted the role of P. vivax as a cause of severe and 
even fatal malaria [3–7]. For this reason, Baird recom-
mended, in his revision of the nomenclature of human 
malaria, to include vivax malaria as an “acute pernicious” 
entity in terms of clinical presentation and evolution [6].
However, conflicting issues emerge from cases of 
severe P. vivax malaria that are increasingly reported in 
the literature, partly because of the lack of a clear defini-
tion of the severity criteria, and partly from the possible 
interference of concomitant morbidities and infections 
on the clinical presentation and outcome [8].
Low platelet counts are commonly encountered in all 
types of malaria, and values lower than 60,000/μL have 
been reported in 29–46 % of patients affected with vivax 
malaria [9, 10]. However, thrombocytopaenia is not 
regarded as a severity biomarker in falciparum malaria, 
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and it has not as yet been validated as an independent 
severity parameter in vivax malaria. Of note, in several 
studies and case reports, severe thrombocytopaenia was 
described as the most prevalent severity sign of vivax 
malaria [11–15]. Therefore, it cannot be excluded that 
the use of such an indicator may lead to an overestima-
tion of P. vivax malaria severity.
Here, it is described a case of imported P. vivax malaria 
characterized by severe thrombocytopaenia along with a 
review of similar cases reported in the literature. Further-
more, it is discussed whether severe thrombocytopae-
nia should be considered a reliable biomarker of P. vivax 
malaria severity.
Case report
A 37-year old male from Pakistan arrived in Italy in July 
2013 to attend a professional course. After few days, he 
developed high grade fever (40 °C) associated with chills, 
headache and one episode of vomiting. He was visited by 
a primary physician who prescribed him cefixime 400 mg/
day and acetaminophen. After 4 days, due to the persis-
tence of fever and the onset of productive cough and 
asthenia, cefixime was changed to levofloxacin (500 mg/
day). However, the fever did not resolve, and therefore the 
patient was taken to the nearest emergency department 
(ED). At presentation, he was febrile (39.5 °C), tachycardic 
(121 beats per min) and hypotensive (90/50  mm Hg); 
there were no meningeal signs and the Glasgow Coma 
Score was normal (15). Oxygen saturation while breathing 
ambient air was 99 %, the respiratory examination and a 
chest radiograph were both normal. Laboratory investiga-
tions were as follows: haemoglobin, 15.9 g/dL; red blood 
cell count, 5.54 × 109/L; total white cell count, 6.3 × 109/L 
(with 85 % neutrophils, 11 % lymphocytes and 4 % mono-
cytes); platelet count, 14 × 109/L. With the exception of 
d-dimer concentration (9376  ng/dL), the other coagula-
tion parameters were within the normal range. Hypona-
tremia (127 mmol/L) was present as well as raised values 
of C reactive protein (126 mg/L), total bilirubin (3.3 mg/
dL), and lactate dehydrogenase (371  U/L). Serum con-
centrations of glucose, liver enzymes, urea and creatinine 
were within normal ranges. An ultrasound scan of the 
abdomen showed no hepatosplenomegaly and a normal 
biliary tract. Legionella and pneumococcus urine antigens 
were negative. A thin blood film showed “malaria para-
sites” that were not identified at the species level by the 
laboratory technician. Due to lack of anti-malarial drugs 
and the expertise for the diagnosis and therapy of malaria, 
the ED physician contacted the Luigi Sacco hospital in 
Milan for assistance. Ten hours after presentation at the 
first ED, the patient was finally admitted to the inten-
sive care unit of Luigi Sacco hospital with a provisional 
diagnosis of “severe malaria”, based on the results of the 
laboratory tests (severe thrombocytopaenia and raised bil-
irubin levels) and the presence of hypotension. On physi-
cal examination, when admitted to the ICU, the patient 
was conscious, fully oriented to time and place with high 
fever (40  °C) and had severe headache. The pulmonary, 
cardiovascular and abdominal examinations were report-
edly unremarkable. Neither signs of bleeding nor skin 
petechiae were detected. No previous history of malaria 
episodes was elicited and no underlying chronic diseases 
were present. The patient was treated with a loading dose 
of intravenous quinine (1200 mg). At treatment inception 
the platelet count was 5 ×  109/L, without haemorrhagic 
manifestations. Examination of the peripheral blood 
smear by the haematologist did not reveal platelet clump-
ing and a blood sample obtained with sodium citrate con-
firmed the finding of low platelet counts thus excluding 
a diagnosis of pseudothrombocytopaenia. In the absence 
of bleeding the haematologist judged as unnecessary the 
use of platelet transfusions. Thick and thin blood smear 
examinations were diagnostic for P. vivax infection with 
schizonts, gametocytes and ring forms being detected 
and a very low parasitaemia (0.1  %). Plasmodium vivax 
monoinfection was subsequently confirmed by DNA 
polymerase chain reaction performed on a stored blood 
sample obtained on admission. Blood and urine cultures 
were obtained but gave negative results. Serology for HIV, 
CMV, dengue virus, leptospirosis, syphilis, Brucella and 
typhoid fever were negative.
Platelet counts showed a rapid increase soon after 
the infusion of quinine (i.e., 13  ×  109/L, 16  ×  109/L, 
20 × 109/L, 32 × 109/L, respectively, after 4, 10, 18 and 
24 h). The following morning an infectious diseases con-
sultation was requested which suggested an interruption 
of intravenous quinine (after two doses administered). 
In consideration of the stable clinical condition and the 
diagnosis of P. vivax malaria the patient was transferred 
to the Infectious Diseases ward where oral chloroquine 
was started to complete the treatment. Parasite clearance 
was observed within 48 h after hospital admission as well 
as improvement or complete disappearance of all accom-
panying signs and symptoms (fever, headache, nausea, 
asthenia, myalgia). After completing a 3-day course of 
chloroquine treatment, and documentation of normal 
glucose 6-phosphate dehydrogenase activity levels, the 
patient was started on oral primaquine (15  mg of base 
in a 26.3  mg tablet per day for 14  days) and discharged 
the fifth day of hospitalization in good clinical condi-
tions and with platelet counts within the normal range 
(223 × 109/L).
Discussion
In this case report, a man from Pakistan with imported P. 
vivax malaria was initially classified as affected by severe 
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malaria and admitted to the ICU on the basis of profound 
thrombocytopaenia. Despite the initial presentation, the 
patient’s clinical course was uneventful and the platelet 
counts recovered very rapidly under anti-malarial treat-
ment [16]. In recent years, an increasing number of case 
reports and hospital-based studies, have questioned the 
notion of “benign tertian malaria” by describing severe 
and even fatal malaria associated with P. vivax infection 
[3–8, 12–15]. In many instances, severe thrombocyto-
paenia was used by the authors of these reports as the 
stand-alone criterion of malaria severity, irrespective of 
the presence of haemorrhagic events and/or other signs 
of disease severity.
However, two relevant aspects deserve to be consid-
ered when interpreting the findings of these studies. The 
first concerns the lack of any specific case definition for 
severe P. vivax malaria and, consequently, the question 
of whether severe thrombocytopaenia should be con-
sidered, in the absence of bleeding, a marker of disease 
severity.
Thrombocytopaenia (i.e., a platelet count below 
150,000/μL) is a frequent haematological finding in 
all types of malaria and it is observed in 29–93.3  % of 
patients with P. vivax malaria [9, 17]. The exact mecha-
nisms underlying the decrease in platelet counts is still 
unknown, but various hypothesis have been advanced 
including immune-mediated phenomena, oxidative 
stress, alterations in splenic function and a direct interac-
tion between the parasite and platelets [18–22]. Recently, 
Coelho and coworkers demonstrated that macrophage-
driven phagocytosis of platelets may be an important 
contributory mechanism and that the mean platelet vol-
ume was greater in thrombocytopaenic patients with 
vivax malaria than in controls [23]. The latter finding is 
particularly interesting because the presence of large cir-
culating platelets and may be viewed as compensatory 
mechanism in order to preserve primary haemostasis. 
Accordingly, bleeding is seldomly observed in the course 
of malaria even among patients with severe thrombocy-
topaenia. So what is the clinical and prognostic signifi-
cance of severe thrombocytopaenia in patients with vivax 
malaria?
Thirty-three case reports of severe thrombocytopaenia 
(median platelet count: 21,000/μL, range: 2000–45,000/
μL) in patients with vivax malaria have been published 
in the medical literature from 1993 to 2014 (the major-
ity after 2006) [11, 12, 15, 24–51]. Ten individuals pre-
sented with haemorrhagic manifestations [27, 28, 30, 35, 
38, 40, 41, 43, 48] and nine received platelet transfusions: 
all patients recovered with the exception of one who died 
because of shock and pancreatitis [45] (Table 1).
Information regarding the relationship between vivax 
malaria and thrombocytopaenia adopted as a criterion 
for assessing malaria severity may be also extracted 
from 17 clinical studies (13 from India [13, 14, 52–62], 
two from Pakistan [63, 64] and one each from Colom-
bia and Sudan [65, 66]). In fifteen of these studies, a cut-
off value of less than 50,000 platelets per μL was used to 
define severe thrombocytopaenia [13, 52–60, 62–66]. 
Overall, platelet counts below 50,000/μL were present 
in 335 out of the 906 cases of severe malaria examined 
(36.9  %), although the prevalence varied significantly 
among the studies, from 12.5 % to 93 % (Table 2), because 
of the different selection criteria employed. Bleeding 
manifestations (mainly epistaxis) were observed in 108 
patients (34.8 %), but only in two patients were they seri-
ous enough to directly contribute to death (i.e., dissemi-
nated intravascular coagulation and gastrointestinal tract 
haemorrhage) [54, 58].
It is noteworthy that mixed P. vivax and P. falciparum 
infections were not ruled out in 14 out of 17 studies [14, 
52, 53, 63–66]. In addition, coexisting infections that 
may contribute to thrombocytopaenia (such as dengue 
fever, leptospirosis or bacterial sepsis) were not excluded 
in the majority of the studies [14, 52–55, 57, 58, 60–66]. 
Regarding the latter issue, a recent study conducted in 
the Brazilian Amazon showed that 17.6  % of patients 
with P. vivax malaria had concomitant dengue infection 
and these had a higher probability to present with haem-
orrhagic manifestations and jaundice [67].
Other studies have focused on the prognostic role of 
thrombocytopaenia in vivax malaria. Leal-Santos and 
coworkers in a cross-sectional study conducted in 186 
patients from the Mato Grosso region showed that mean 
platelet volume and platelet distribution width (PDW) 
were significantly associated with the presence of warn-
ing signs of severe and complicated malaria (i.e., anae-
mia, hypotension and elevated creatinine levels) with 
odds ratios (OR) of 3.47 and 5.44, respectively [68]. In 
keeping with the above mentioned results, a large study 
conducted in Papua New Guinea showed that the great-
est risk of severe thrombocytopaenia was associated with 
P. falciparum malaria (OR 6.03 vs 3.73 for P. vivax). How-
ever, the mortality risk for patients with severe thrombo-
cytopaenia was higher among patients without malaria 
(7.9  %) than among those with P. falciparum (2.1  %) or 
P. vivax (1.5  %) malaria [69]. The authors also found a 
16-fold higher risk of death when severe thrombocyto-
paenia was associated with severe anaemia (haemoglobin 
concentration below 5 mg/dL), and concluded that severe 
thrombocytopaenia should serve as a warning sign of 
poor outcome in patients with malaria particularly when 
it is accompanied by severe anaemia. Based on their find-
ings, Lampah and coworkers proposed a threshold of 
≤20,000 platelets/μL as a defining severity criterion for 
both P. falciparum and P. vivax malaria [69].
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However, in a recent study conducted in Brazil and 
India on 778 patients with documented P. vivax mono-
infection, platelet counts showed a very poor discrimina-
tive performance to identify criteria of severe disease and 
the authors concluded that thrombocytopaenia should 
not be used to identify patients with P. vivax complica-
tions [70].
The second issue that deserves to be addressed when 
considering disease severity regards mortality. In other 
words: did patients whose death was attributed to 
P. vivax malaria die of malaria or with malaria?
This issue has been addressed in one study only which 
was conducted in Brazil and reported the autopsy find-
ings of 17 patients who died of P. vivax malaria [5]. The 
authors reported during the study period (1996–2010) 
a case-fatality rate (CFR) for P. vivax malaria of 0.011 % 
(19/170.286), but in only four of the seventeen patients 
who underwent autopsy death could be exclusively attrib-
uted to P. vivax malaria, resulting in a CFR of 0.002 % [5]. 
Of note, the CFR of P. vivax malaria was 16-fold lower 
than the one observed for P. falciparum malaria in the 
same period (0.032  %, 12/36.854) [5]. In another study 
conducted in Papua, Indonesia, between January 2004 and 
September 2009, a post hoc clinical death audit of cases of 
pure P. vivax malaria resulted in a CFR of 0.12 per 1000 
infections [71]. Of note, of the six fatal cases for whom 
vivax malaria was considered the primary cause of death, 
four were young children of less than 2 years of age (two 
of whom were malnourished), and the other two were 
adults in whom sepsis was concomitantly documented.
Moreover, in a retrospective analysis of 12.769 cases 
of imported P. vivax malaria observed in the UK over 
27 years (1987–2013), seven deaths were registered, giv-
ing an overall mortality of 0.05  %. The median age of 
deceased patients was 72 years, while no deaths occurred 
in the 9927 patients aged less than 50 years [72]. In the 
two studies regarding imported P. vivax malaria con-
ducted by the TropNetEurope and the GeoSentinel net-
work, reporting respectively 618 and 278 patients (either 
travellers or immigrants), no deaths were recorded 
among patients affected by this species of Plasmodium 
[73, 74].
Thus, based on available data, the mortality risk of 
P. vivax malaria seems to be different in endemic areas 
as opposed to what is observed in cases of imported 
disease in Europe or USA. In endemic areas, the risk of 
death is low and influenced by several factors, such as 
very young age, severe anaemia at presentation, malnu-
trition, pregnancy, coexisting comorbidities and con-
current infections [69–71, 75]. When imported P. vivax 
malaria is considered, the risk of death is generally 
absent or negligible and principally influenced by old age. 
Another important issue that should be considered when 
comparing malaria mortality is the lack of high level sup-
portive care in many countries where malaria is endemic 
a factor that explains the better outcome observed in 
non-endemic countries where high-quality healthcare is 
available [76]. Despite these considerations it should be 
emphasized that the risk of death directly attributable to 
P. vivax malaria should not be overlooked.
In conclusion, given the lack of high quality studies and 
the fact that several confounding factors cannot be ruled 
out in the majority of case reports and studies published 
so far, the role of severe thrombocytopaenia as an indi-
cator of P. vivax malaria severity cannot at present nei-
ther be discarded nor confirmed and it deserves to be 
addressed in well conducted prospective studies in both 
endemic and non-endemic countries.
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